Piper Jaffray Downgrades Spring Bank Pharmaceuticals (SBPH) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mailGet Alerts SBPH Hot Sheet
Price: $1.21 --0%
Rating Summary:
3 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Rating Summary:
3 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Join SI Premium – FREE
Piper Jaffray analyst Edward Tenthoff downgraded Spring Bank Pharmaceuticals (NASDAQ: SBPH) from Overweight to Neutral with a price target of $1.70 (from $10.00).
For an analyst ratings summary and ratings history on Spring Bank Pharmaceuticals click here. For more ratings news on Spring Bank Pharmaceuticals click here.
Shares of Spring Bank Pharmaceuticals closed at $3.61 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Downgrades Black Hills Corp (BKH) to Hold on Valuation
- Wayfair (W) PT Raised to $140 at Bernstein SocGen Group
- Goldman Sachs Downgrades Regis Resources Ltd. (RRL:AU) (RGRNF) to Sell
Create E-mail Alert Related Categories
Analyst Comments, DowngradesRelated Entities
Piper Jaffray, Edward TenthoffSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
